Novartis Drug Combination Gets FDA Approval for Thyroid Cancer
May 07 2018 - 8:49AM
Dow Jones News
By Donato Paolo Mancini
The U.S. Food and Drug Administration approved Friday the
combined use of Novartis's (NOVN.EB) Tafinlar and Mekinist for the
treatment of a type of thyroid cancer.
The new use is for the treatment of a genetic variant of
anaplastic thyroid cancer that cannot be removed by surgery or has
become metastatic, the regulator said.
Both drugs are approved for use, both in combination and
individually, for the treatment of a type of melanoma. In
combination, they're also used to treat a type of metastatic lung
cancer. All indications, including last week's, are for cancers
that are mutation-positive to BRAF V600E, an abnormal gene.
Novartis said last month that first-quarter sales of Tafinlar
and Mekinist grew 33% to $267 million.
The company's oncology division, long affected by generic price
erosion of its former blockbuster Gleevec/Glivec, was helped to
swing to a profit by the two drugs.
Write to Donato Paolo Mancini at
donatopaolo.mancini@dowjones.com
(END) Dow Jones Newswires
May 07, 2018 08:34 ET (12:34 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024